- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novavax Inc (NVAX)
Find here information about Novavax (NVAX) share price. You can find more details about NASDAQ: NVAX by going to one of the sections listed on this page such as historical data, price charts, Novavax stock technical analysis and more.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.230
9.600
52 wk Range
5.010
10.645
NVAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.2309.600
52 wk Range
5.01010.645
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
12.889
Upside
+36.53%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Novavax Company Profile
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax Inc Earnings Call Summary for Q3/2025
- Novavax Q3 2025 revenue of $70.45M beat forecasts by 26.57%, but EPS loss of $1.25 was 130.33% worse than expected, causing shares to dip 1.11% in pre-market trading
- Total revenue declined to $70M from $85M year-over-year, with product sales dropping to $13M while licensing and royalties contributed $57M; company reported a $202M net loss
- Management raised 2025 adjusted revenue guidance to $1,040-$1,060M and announced a strategic focus on cost reduction, with SG&A expenses already cut by 55%
- CEO John Jacobs emphasized success in strategic priorities and a new focus on 'amplifying the impact of our technology platform through collaborations'
- Novavax targets non-GAAP profitability by 2028 and expects significant growth in royalties from its Sanofi collaboration in 2026-2027
Last Updated: 06/11/2025, 16:28
Read Full TranscriptCompare NVAX to Peers and Sector
Metrics to compare | NVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 4.5x | −2.3x | −0.6x | |
PEG Ratio | 0.02 | 0.09 | 0.00 | |
Price/Book | −9.8x | 3.1x | 2.6x | |
Price / LTM Sales | 1.4x | 8.2x | 3.4x | |
Upside (Analyst Target) | 19.2% | 148.7% | 43.4% | |
Fair Value Upside | Unlock | 7.9% | 6.3% | Unlock |
Analyst Ratings
5 Buy
1 Hold
3 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 12.889
(+36.53% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-1.25 / -0.5427
Revenue / Forecast
70.45M / 55.66M
People Also Watch
FAQ
What Is the Novavax (NVAX) Share Price Today?
The live Novavax share price today is 9.440
What Stock Exchange Does Novavax (NVAX) Trade On?
Novavax is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Novavax?
The stock symbol (also called a 'ticker') for Novavax is "NVAX."
What Is the Current Novavax Market Cap?
As of today, Novavax market capitalisation is 1.53B.
What Is Novavax's (NVAX) Earnings Per Share (TTM)?
The Novavax EPS is currently 2.07 (Trailing Twelve Months).
When Is the Next Novavax Earnings Date?
Novavax's next earnings report will be released on 04 Mar 2026.
Is NVAX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Novavax moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Novavax Stock Split?
Novavax has split 1 times. (See the NVAX stock split history page for full effective split date and price information.)
How Many Employees Does Novavax Have?
Novavax has 952 employees.
What is the current trading status of Novavax (NVAX)?
As of 29 Jan 2026, Novavax (NVAX) is trading at a price of 9.440, with a previous close of 9.230. The stock has fluctuated within a day range of 9.230 to 9.600, while its 52-week range spans from 5.010 to 10.645.
What Is Novavax (NVAX) Price Target According to Analysts?
The average 12-month price target for Novavax is USD12.889, with a high estimate of USD25 and a low estimate of USD6. 5 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an +36.53% Upside potential.
What Is the NVAX Premarket Price?
NVAX's last pre-market stock price is 9.240. The pre-market share volume is 59,230.000, and the stock has decreased by 0.010, or 0.110%.
What Is the NVAX After Hours Price?
NVAX's last after hours stock price is 9.436, the stock has decreased by -0.004, or -0.040%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.